News Kaken details the data behind its PI3K inhibitor filing Kaken has revealed the data that supported its recent marketing application for serabelisib as a treatment for vascular malformations in Japan.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
